Ferriprox is owned by Chiesi.
Ferriprox contains Deferiprone.
Ferriprox has a total of 6 drug patents out of which 0 drug patents have expired.
Ferriprox was authorised for market use on 09 September, 2015.
Ferriprox is available in solution;oral dosage forms.
Ferriprox can be used as method of treating transfusional iron overload.
The generics of Ferriprox are possible to be released after 25 October, 2038.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(6 years from now) | |
US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Apr 30, 2024 |
Orphan Drug Exclusivity (ODE) | Apr 30, 2028 |
Drugs and Companies using DEFERIPRONE ingredient
Market Authorisation Date: 09 September, 2015
Treatment: Method of treating transfusional iron overload
Dosage: SOLUTION;ORAL
11
United States
4
Canada
3
China
2
Australia
2
EA
2
Israel
2
Korea, Republic of
2
New Zealand
2
Mexico
2
Brazil
2
European Union
1
Croatia
1
IB
1
Denmark
1
Spain
1
Costa Rica
1
Cyprus
1
Singapore
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Japan
1
Morocco
1
Hong Kong
1
Slovenia
1
RS
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic